These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33761646)

  • 1. The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.
    Zhou J; Chen Y; Yu J; Li T; Lu Z; Chen Y; Zhang X; Ye F
    Medicine (Baltimore); 2021 Mar; 100(12):e24884. PubMed ID: 33761646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials.
    Liu H; Li Y; Jin Y; Li X; Wang D; Yu X; Jiang Z; Yin G; Chen S; Zhang X; Meng D; Yu W; Jiang W; Zhang F
    Phytother Res; 2024 Jul; 38(7):3801-3824. PubMed ID: 38886838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
    Front Immunol; 2022; 13():949746. PubMed ID: 36159792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
    Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
    Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Malik A; Nadeem M; Malik MI
    Clin J Gastroenterol; 2021 Dec; 14(6):1579-1586. PubMed ID: 34370218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
    Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
    Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tang G; Zhang L; Tao J; Wei Z
    Phytother Res; 2021 Aug; 35(8):4183-4193. PubMed ID: 33728708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
    Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
    Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
    J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.
    Hadi A; Mohammadi H; Miraghajani M; Ghaedi E
    Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449
    [No Abstract]   [Full Text] [Related]  

  • 13. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats.
    Yin Y; Liu H; Zheng Z; Lu R; Jiang Z
    Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Loman BR; Hernández-Saavedra D; An R; Rector RS
    Nutr Rev; 2018 Nov; 76(11):822-839. PubMed ID: 30113661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Yi H; Sun W; Yu H; Tao W; Yu X; Jia D; Liu Y; Pandol SJ; Li L
    Drugs; 2024 Apr; 84(4):425-439. PubMed ID: 38478331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acupoint therapy on nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Bi Y; Yin B; Fan G; Xia Y; Huang J; Li A; Lin Y
    Complement Ther Clin Pract; 2021 May; 43():101376. PubMed ID: 33813176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Change in plasma nesfatin-1 concentration within high-fat diet induced nonalcoholic fatty liver disease rat models].
    Wu R; Chen Z; Xu Y; Ge J; Lü X
    Wei Sheng Yan Jiu; 2016 May; 45(3):452-7. PubMed ID: 27459811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Guo XF; Wang C; Yang T; Li S; Li KL; Li D
    Food Funct; 2020 Sep; 11(9):7389-7399. PubMed ID: 32966467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.